Discovery opens new possibilities for regenerative medicine
Harvard Stem Cell Institute researchers at Boston Children’s Hospital have reprogrammed mature blood cells from mice into blood-forming hematopoietic stem cells (HSCs) using a cocktail of eight genetic switches called transcription factors. The reprogrammed cells, which the researchers have dubbed induced HSCs (iHSCs), have the functional hallmarks of HSCs, are able to self-renew like HSCs, and can give rise to all of the cellular components of the blood like HSCs.
The findings mark a significant step toward one of the most sought-after goals of regenerative medicine: the ability to produce HSCs suitable for transplantation using more mature or differentiated cells. Blood stem cell transplants (also known as bone marrow transplants) have been saving the lives of patients for almost three decades, but have been limited by the difficulty of obtaining good cell matches for transplantation.
HSCs are the basic starting material for all blood stem cell transplants, regardless of their source (bone marrow, umbilical cord blood, peripheral blood). The success of any individual patient's transplant correlates with the number of HSCs available for transplant: the more cells, the more likely the transplant will take hold. However, HSCs are quite rare.
"HSCs only comprise about 1 in every 20,000 cells in the bone marrow," Rossi said. "If we could generate HSCs from a patient's other cells, it could be transformative for transplant medicine and for our ability to model diseases of blood development."
In their study, Rossi and his collaborators, including lead author Jonah Riddell, PhD, screened gene expression in 40 different types of blood and blood progenitor cells from mice. From this screen they identified 36 transcription factors—genes that control when other genes are turned on and off—that are expressed exclusively in HSCs, not in cells that arise from them.
"Blood cell production invariably goes in one direction: from stem cells, to progenitors, to mature effector cells,” Rossi explained. "We wanted to reverse the process and derive HSCs from differentiated blood cells using transcription factors that we found were specific to HSCs."
In a series of mouse transplantation experiments, Rossi's team found that six—Hlf, Runx1t1, Pbx1, Lmo2, Zfp37, and Prdm5—of the 36 factors, plus two additional factors not originally identified in their screen—Mycn and Meis1—were sufficient to robustly reprogram two kinds of blood progenitor cells (pro/pre B cells and common myeloid progenitor cells) into iHSCs.
Rossi's team reprogrammed their source cells by exposing them to viruses containing the genes for all eight factors and a molecular switch that turned the factor genes on in the presence of doxycycline. They then transplanted the exposed cells into recipient mice and activated the genes by giving the mice doxycycline. The resulting iHSCs were capable of generating the entire blood cell repertoire in the transplanted mice, showing that they had gained the ability to differentiate into all blood lineages.
Harvard Stem Cell Institute Principal; Faculty member Stuart Orkin, MD, one of the leaders of Dana-Farber/Boston Children's Cancer and Blood Disorders Center and a co-author on the paper, noted that the use of mice as a kind of reactor for reprogramming marks a novel direction in HSC research.
"In the blood research field no one has the conditions to expand HSCs in the tissue culture dish," he said. "By transplanting the virally exposed cells into mice, Derrick took advantage of the signaling and environmental cues HSCs would normally experience." Orkin added that iHSCs are nearly indistinguishable from normal HSCs at the transcriptional level.
As they stand, the findings are far from being translated to the transplantation clinic. Still to be answered are the precise contribution of each of the eight factors to the reprogramming process and whether approaches that do not rely on viruses and transcription factors can have similar success. It is also not yet known whether the same results can be achieved using human cells or whether other, non-blood cells can be reprogrammed to iHSCs.
"This discovery could have a radical effect on transplantation," Orkin said. "You could have gene-matched donors, you could use a patient's own cells to create iHSCs. It's a long way off, but this is a good step in the right direction."
The study was supported by the Harvard Stem Cell Institute, the National Heart, Lung and Blood Institute (grant numbers RO1HL107630 and U01HL100001), the National Institute of Aging (grant number R00AG029760), the National institute of Diabetes and Digestive and Kidney Diseases (grant number UO1DK072473-01), GlaxoSmithKline, the Leona M. and Harry B. Hemlsley Charitable Trust, and the New York Stem Cell Foundation . Dr. Orkin is an investigator with the Howard Hughes Medical Institute.
Cited: Riddel, J., et al. Reprogramming committed murine blood cells to induced hematopoietic stem cells with defined factors. Cell. April 24, 2014
Article provided by Boston Children's Hospital. Written by Thomas Ulrich.